Catalent (CTLT) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Catalent (NYSE: CTLT) recently:

  • 2/7/2018 – Catalent was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 2/6/2018 – Catalent was given a new $49.00 price target on by analysts at Bank of America Corp. They now have a “buy” rating on the stock.
  • 2/6/2018 – Catalent was downgraded by analysts at Stephens from an “overweight” rating to an “equal weight” rating.
  • 2/5/2018 – Catalent was given a new $48.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 1/24/2018 – Catalent is now covered by analysts at Goldman Sachs Group Inc. They set a “buy” rating and a $50.00 price target on the stock.
  • 1/18/2018 – Catalent was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/17/2018 – Catalent was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $48.00 price target on the stock. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/9/2018 – Catalent was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 1/5/2018 – Catalent is now covered by analysts at First Analysis. They set an “equal weight” rating on the stock.
  • 12/20/2017 – Catalent was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

Catalent Inc (NYSE CTLT) opened at $40.47 on Monday. Catalent Inc has a 1 year low of $27.48 and a 1 year high of $47.87. The company has a debt-to-equity ratio of 2.66, a quick ratio of 2.49 and a current ratio of 2.22. The stock has a market cap of $5,395.42, a P/E ratio of 71.00, a price-to-earnings-growth ratio of 2.32 and a beta of 1.47.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The company had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. During the same period last year, the firm posted $0.27 EPS. Catalent’s revenue for the quarter was up 25.3% compared to the same quarter last year. equities analysts predict that Catalent Inc will post 1.53 earnings per share for the current fiscal year.

In other news, Director Uwe Roehrhoff bought 7,500 shares of the business’s stock in a transaction dated Tuesday, November 21st. The stock was purchased at an average cost of $39.22 per share, with a total value of $294,150.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply